Everolimus in tuberous sclerosis patients with intractable epilepsy: A treatment option?

European Journal of Paediatric Neurology

Volumn 17, Issue 6, 2013, Pages 631-638

  Wiegand, Gert ^a   May, Theodor W ^b   Ostertag, Philipp ^a   Boor, Rainer ^c   Stephani, Ulrich ^a   Franz, David Neal ^d  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b EPILEPSY CENTER BETHEL   (Germany)

^c Northern German Epilepsy Center for Children and Adolescents   (Germany)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Everolimus; Intractable epilepsy; mTOR; Refractory seizures; Tuberous sclerosis

Indexed keywords

EVEROLIMUS;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANTICONVULSANT ACTIVITY; APHTHOUS ULCER; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHILD; CHLORIDE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMMON COLD; COMPASSIONATE USE; CONJUNCTIVITIS; CREATININE BLOOD LEVEL; CROUP; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE COUNT; FEMALE; FLUSHING; FUNGAL GENITAL INFECTION; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROENTERITIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTRIGLYCERIDEMIA; INFECTION; INTRACTABLE EPILEPSY; LIFE THREAT; MALE; NONPARAMETRIC TEST; OTITIS MEDIA; PETECHIA; PHARYNGITIS; PNEUMONIA; PRIORITY JOURNAL; PYURIA; RASH; RHINITIS; SEIZURE; SIDE EFFECT; STOMATITIS; THROMBOCYTE COUNT; THROMBOCYTOSIS; TRIACYLGLYCEROL BLOOD LEVEL; TUBEROUS SCLEROSIS; UPPER RESPIRATORY TRACT INFECTION; UREA BLOOD LEVEL;

EVEROLIMUS; INTRACTABLE EPILEPSY; MTOR; REFRACTORY SEIZURES; TUBEROUS SCLEROSIS;

ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; EPILEPSY; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; SIROLIMUS; STATISTICS, NONPARAMETRIC; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 84887989959     PISSN: 10903798     EISSN: 15322130     Source Type: Journal    
DOI: 10.1016/j.ejpn.2013.06.002     Document Type: Article

References (35)

1. P. Curatolo, S. Jozwiak, R. Nabbout On behalf of the participants of the TSC Consensus Meeting for SEGA und Epilepsy Management Management of epilepsy associated with tuberous sclerosis complex (TSC): clinical recommendations Eur J Paediatr Neurol 16 2012 582 586 10.1016/j.ejpn.2012.05.004
2. L.H. Zeng, L. Xu, D.H. Gutmann, and M. Wong Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex Ann Neurol 63 2008 444 453
3. D.N. Franz Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis Expert Rev Anticancer Ther 11 8 2011 1181 1192
4. D.A. Krueger, M.M. Care, K. Agricola, C. Tudor, M. Mays, and D.N. Franz Everolimus long-term safety and efficacy in subependymal giant-cell astrocytoma Neurology 80 2013 574 580
5. M.P. Curran Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex Paediatr Drugs 14 1 2012 51 60
6. M. Perek-Polnik, S. Jozwiak, E. Jurkiewicz, D. Perek, and K. Kotulska Effective everolimus treatment of inoperable, life-threatening subependymal giant cell astrocytoma and intractable epilepsy in patient with tuberous sclerosis complex Eur J Paediatr Neurol 16 2012 83 85
7. J. Muncy, I.J. Butler, and M.K. Koening Rapamycin reduces seizure frequency in tuberous sclerosis complex J Child Neurol 24 4 2009 477
8. D.A. Krueger, M.M. Care, K. Holland, K. Agricola, C. Tudor, P. Mangeshkar, K.A. Wilson, A. Byars, T. Sahmoud, and D.N. Franz Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis N Engl J Med 363 2010 1801 1811
9. S.F. Tavazoie, V.A. Alvarez, D.A. Ridenour, D.J. Kwiatkowski, and B.L. Sabatini Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2 Nat Neurosci 8 12 2005 Dec 1727 1734
10. J.M. Tillema, J.L. Leach, D.A. Krueger, and D.N. Franz Everolimus alters white matter diffusion in tuberous sclerosis complex Neurology 78 8 2012 Feb 21 526 531
11. R.C. Ryther, and M. Wong Mammalian target of rapamycin (mTOR) inhibition: potential for antiseizure, antiepileptogenic, and epileptostatic therapy Curr Neurol Neurosci Rep 12 4 2012 Aug 410 418
12. M. Wong Crino PB mTOR and epileptogenesis in developmental brain malformations J.L. Noebels, M. Avoli, M.A. Rogawski, R.W. Olsen, A.V. Delgado-Escueta, Jasper's basic mechanisms of the epilepsies 4th ed. 2012 National Center for Biotechnology Information (US) Bethesda (MD)
13. P. Kwan, A. Arzimanoglou, A.T. Berg, M.J. Brodie, W. Allen Hauser, G. Mathern, S.L. Moshé, E. Perucca, S. Wiebe, and J. French Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies Epilepsia 51 6 2010 1069 1077
14. E.S. Roach, M.R. Gomez, and H. Northrup Tuberous sclerosis consensus conference: revised clinical diagnostic criteria J Child Neurol 13 1998 624 628
15. A.T. Berg, S.F. Berkovic, M.J. Brodie, J. Buchhalter, J.H. Helen Cross, W. van Emde Boas, J. Engel, J. French, T.A. Glauser, G.W. Mathern, S.L. Moshé, D. Nordli, P. Plouin, and I.E. Scheffer Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE commission on classification and terminology, 2005-2009 Epilepsia 51 4 2010 676 685
16. J.A.H.F. Baudhuin, G. Rabending, U. Stephani, and R. Boor E-Health in der pädiatrischen Epileptologie Z für Epileptologie 23 2010 47 52
17. G. Rabending, and U. Runge Der elektronische Behandlungskalender (Epivista) Z für Epileptologie 15 2002 2 5
18. C. Doege, T.W. May, M. Siniatchkin, S. von Spiczak, U. Stephani, and R. Boor Myoclonic astatic epilepsy (Doose syndrome) - a lamotrigine responsive epilepsy? Eur J Paediatr Neurol 17 2013 29 35
19. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events, version 3.0. (http://ctep.cancer.gov).
20. D.R. Cox, and A. Stuart Some quick sign tests for trend in location and dispersion Biometrika 42 1955 80 95
21. P.F. Thall, and S.C. Vail Some covariance models for longitudinal count data with overdispersion Biometrics 46 1990 657 671
22. P. Curatolo, R. Bombardieri, M. Verdecchia, and S. Seri Intractable seizures in tuberous sclerosis complex: from molecular pathogenesis to the rationale for treatment J Child Neurol 20 2005 318 325
23. J.J. Bissler, J.C. Kingswood, and E. Radzikowska Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial Lancet 381 2013 Mar 9 817 824
24. D.N. Franz, E. Belousova, and S. Sparagana Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial Lancet 381 9861 2013 Jan 12 125 132
25. L. Vernacchio, R. Vezina, A.A. Mitchell, S.M. Lesko, A.G. Plaut, and W.K. David Diarrhea in American infants and young children in the community setting: incidence, clinical presentation and microbiology Pediatr Infect Dis J 25 1 2006 2 7
26. T. Heikkinen, and A. Järvinen The common cold Lancet 361 2003 51 59
27. K. Kotulska, D. Chmielewski, J. Borkowska, E. Jurkiewicz, D. Kuczyński, T. Kmieć, B. Lojszczyk, D. Dunin-Wa̧sowicz, and S. Jóźwiak Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex Eur J Paediatr Neurol 2013 Apr 6 10.1016/j.ejpn.2013.03.002
28. L. Meikle, K. Pollizzi, A. Egnor, I. Kramvis, H. Lane, M. Sahin, and D.J. Kwiatkowski Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function J Neurosci 28 21 2008 May 21 5422 5432
29. A.S. Galanopoulou, J.A. Gorter, and C. Cepeda Finding a better drug for epilepsy: the mTOR pathway as an antiepileptogenic target Epilepsia 53 7 2012 Jul 1119 1130
30. M. Wong Mammalian target of rapamycin (mTOR) inhibition as a potential anti-epileptogenic therapy: from tuberous sclerosis to common acquired epilepsies Epilepsia 51 1 2010 27 36
31. B. Zhang, S.S. McDaniel, N.R. Rensing, and M. Wong Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex PLoS One 8 2 2013 Epub 2013 Feb 20
32. S.S. McDaniel, N.R. Rensing, L.L. Thio, K.A. Yamada, and M. Wong The ketogenic diet inhibits the mammalian target of apamycin (mTOR) pathway Epilepsia 52 3 2011 Mar e7 e11
33. A.S. Don, C.K. Tsang, T.M. Kazdoba, G. D'Arcangelo, W. Young, and X.F. Zheng Targeting mTOR as a novel therapeutic strategy for traumatic CNS injuries Drug Discov Today 17 15-16 2012 Aug 861 868
34. E. Raffo, A. Coppola, T. Ono, S.W. Briggs, and A.S. Galanopoulou A pulse rapamycin therapy for infantile spasms and associated cognitive decline Neurobiol Dis 43 2 2011 Aug 322 329
35. G. Lenz, and J. Avruch Glutamatergic regulation of the p70S6 kinase in primary mouse neurons J Biol Chem 280 46 2005 Nov 18 38121 38124